Oral administration of synthetic retinoid Am80 (tamibarotene) decreases brain β-amyloid peptides in APP23 mice

Biological and Pharmaceutical Bulletin

Volumn 32, Issue 7, 2009, Pages 1307-1309

  Kawahara, Kohichi ^a   Nishi, Kentaro ^a   Suenobu, Michita ^a   Ohtsuka, Hideyuki ^a   Maeda, Akira ^a   Nagatomo, Kenichiro ^a   Kuniyasu, Akihiko ^a   Staufenbiel, Matthias ^b   Nakagomi, Madoka ^c   Shudo, Koichi ^c   Nakayama, Hitoshi ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Kawasaki   (Japan)

Author keywords

amyloid; Alzheimer's disease; Am80; Retinoid; Tamibarotene

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; TAMIBAROTENE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG POTENCY; ENZYME LINKED IMMUNOSORBENT ASSAY; LEARNING; MALE; MAZE TEST; MEMORY; MOUSE; NONHUMAN; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BENZOATES; BRAIN; DISEASE MODELS, ANIMAL; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; RETINOIDS; TETRAHYDRONAPHTHALENES;

EID: 67650717654     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.32.1307     Document Type: Article

References (22)

1. Selkoe D. J., Ann. Intern. Med., 140, 627-638 (2004).
2. Corcoran J. P., So P. L., Maden M., Eur. J. Neurosci., 20, 896-902 (2004).
3. Tippmann F., Hundt J., Schneider A., Endres K., Fahrenholz F., FASEB J., 23 (2009), in press.
4. Prinzen C., Muller U., Endres K., Fahrenholz F., Postina R., FASEB J., 19, 1522-1524 (2005).
5. Jacobsen J. S., Comery T. A., Martone R. L., Elokdah H., Crandall D. L., Oganesian A., Aschmies S., Kirksey Y., Gonzales C., Xu J., Zhou H., Atchison K., Wagner E., Zaleska M. M., Das I., Arias R. L., Bard J., Riddell D., Gardell S. J., Abou-Gharbia M., Robichaud A., Magolda R., Vlasuk G. P., Bjornsson T., Reinhart P. H., Pangalos M. N., Proc. Natl. Acad. Sci. U.S.A., 105, 8754-8759 (2008).
6. Lansink M., Kooistra T., Blood, 88, 531-541 (1996).
7. Goodman A. B., Pardee A. B., Proc. Natl. Acad. Sci. U.S.A., 100, 2901-2905 (2003).
8. Shudo K., Fukasawa H., Nakagomi M., Yamagata N., Curr. Alzheimer Res., 6, 302-311 (2009).
9. Shudo K., Kagechika H., Yamazaki N., Igarashi M., Takeda C., Biol. Pharm. Bull., 27, 1887-1889 (2004).
10. Sturchler-Pierrat C., Abramowski D., Duke M., Wiederhold K. H., Mistl C., Rothacher S., Ledermann B., Burki K., Frey P., Paganetti P. A., Waridel C., Calhoun M. E., Jucker M., Probst A., Staufenbiel M., Sommer B., Proc. Natl. Acad. Sci. U.S.A., 94, 13287-13292 (1997).
11. Kagechika H., Kawachi E., Hashimoto Y., Shudo K., Chem. Pharm. Bull., 32, 4209-4212 (1984).
12. Ishido M., Shudo K., Biol. Pharm. Bull., 32, 157-159 (2009).
13. Huang S. M., Mouri A., Kokubo H., Nakajima R., Suemoto T., Higuchi M., Staufenbiel M., Noda Y., Yamaguchi H., Nabeshima T., Saido T. C., Iwata N., J. Biol. Chem., 281, 17941-17951 (2006).
14. Morris R., J. Neurosci. Methods, 11, 47-60 (1984).
15. Wyss-Coray T., Loike J. D., Brionne T. C., Lu E., Anankov R., Yan F., Silverstein S. C., Husemann J., Nat. Med., 9, 453-457 (2003).
16. El Khoury J., Toft M., Hickmann S. E., Means T. K., Terada K., Geula C., Luster A. D., Nat. Med., 13, 432-438 (2007).
17. Koistinaho M., Lin S., Wu X., Esterman M., Koger D., Hanson J., Higgs R., Liu F., Malkani S., Bales K. R., Paul S. M., Nat. Med., 10, 719-726 (2004).
18. Simizu E., Kawahara K., Kajizono M., Sawada M., Nakayama H., J. Immunol., 181, 6503-6513 (2008).
19. Hickman S. E., Allison E. K., El Khoury J., J. Neurosci., 28, 8354-8360 (2008).
20. Iwata M., Eshima Y., Kagechika H., Int. Immunol., 15, 1017-1025 (2003).
21. Ding Y., Qiao A., Wang Z., Goodwin J. S., Lee E. S., Block M. L., Allsbrook M., McDonald M. P., Fan G. H., J. Neurosci., 28, 11622-11634 (2008).
22. Van Dam D., D'Hooge R., Staufenbiel M., Van Ginneken C., Van Meir F., De Deyn P. P., Eur. J. Neurosci., 17, 388-396 (2003).